Invested AU$965,400 in Bionomics, a biopharmaceutical company focused on central nervous system disorders, alongside investors including Apeiron Investments, Biotech Value Fund, Merck, Mike Novogratz, and Peter Thiel.Invested US$1,000,000 in Alto Neuroscience, which is developing a pipeline of precision psychiatry medicines using its proprietary AI-based brain biomarker platform.Launched Psychedelic Palliative Care by Novamind, a specialty program to research and scale access to mental healthcare for patients with chronic and serious illness.Launched Frontline Ketamine-Assisted Psychotherapy (Frontline KAP) pilot program to address the widespread COVID-19-related stress and trauma faced by healthcare workers.
#NOVAMIND LOGO TRIAL#
Bionomics' phase II clinical trial of BNC210 for post-traumatic stress disorder.Karuna's phase III clinical trial of KarXT for schizophrenia.Merck's phase II clinical trial of MK-1942 for treatment-resistant depression.Contracted for eight clinical trials including:.Granted DEA Schedule 1 licenses for psilocybin research, a key prerequisite for hosting clinical trials studying psilocybin-assisted psychotherapy.Expanded clinical research network to three total sites featuring specialized staff and infrastructure to support the unique needs of psychedelic clinical trials.Opened a dedicated client call center to centralize clinic administration services and maintain excellent client services while rapidly growing the Company's network of clinics.Clinic #8, Park City, Utah, to open in early 2022.Clinic #7, Salt Lake City, Utah, to open in December 2021.Updated guidance for opening new clinics, adjusting for construction and supply chain disruptions caused by the COVID-19 pandemic:.Strengthened Novamind's clinic network with the addition of two clinics all six locations offer a variety of innovative mental health services, individualized treatment plans and speciality programming for treatment-resistant illnesses.The Company has since resolved the situation, and going forward, will take the required corrective measures.įY2021 Operating Results and Subsequent Events Today the Company filed its financial statements later than anticipated due to unforeseen delays with its audit.
I want to thank our patients, employees, partners and investors, and look forward to rapidly expanding our model to meet demand for psychedelic medicine and other innovative mental health treatments." Our unique business model serving both patients and drug developers is growing significantly, reflected by an expanded clinic network, new clinical programs and research partnerships, and strong additions to our staff and leadership. Yaron Conforti, CEO and Director, commented: "Novamind had strong financial and operating performance in its first year as a public company. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified. (CSE:NM | OTCQB:NVMDF | FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, reported its audited financial results for the twelve months ended J("FY2021"). TORONTO, ON / ACCESSWIRE / Novem/ Novamind Inc. Granted DEA Schedule 1 licenses for psilocybin research.Expanded network to six clinics and three clinical research sites.
0 kommentar(er)
